Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis

BACKGROUND: A promising arsenal of histone deacetylase (HDAC)-targeted treatment has emerged in the past decade, as the abnormal targeting or retention of HDACs to DNA regulatory regions often occurs in many cancers. Head and neck squamous cell carcinoma (HNSCC) is one of the most aggressive maligna...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Leilei, Gao, Lixia, Shay, Chloe, Lang, Liwei, Lv, Fenglin, Teng, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379952/
https://www.ncbi.nlm.nih.gov/pubmed/30777099
http://dx.doi.org/10.1186/s13046-019-1080-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379952/
https://www.ncbi.nlm.nih.gov/pubmed/30777099
http://dx.doi.org/10.1186/s13046-019-1080-8

Ejemplares similares